School of Public Health, The University of Queensland, Brisbane, Australia.
Centre for Health Services Research, The University of Queensland, Brisbane, Australia.
AIDS Behav. 2023 Feb;27(2):618-627. doi: 10.1007/s10461-022-03797-0. Epub 2022 Jul 22.
People living with HIV (PLHIV) have high rates of tobacco smoking. Nicotine vaping products (NVPs) may promote tobacco smoking cessation and/or harm reduction. This study aimed to trial the feasibility of NVPs for promoting tobacco smoking cessation among PLHIV. The Tobacco Harm Reduction with Vaporised Nicotine (THRiVe) study was a mixed-methods trial among 29 PLHIV who used tobacco daily. Participants trialled a 12-week intervention of NVPs. This study reports descriptive analyses of quantitative data on tobacco abstinence and associated adverse events. Short-term abstinence (7-day point prevalence; i.e., no tobacco use for 7 days) was achieved by 35% of participants at Week 12 and 31% reported short-term abstinence at Week 24. Sustained medium-term abstinence (8 weeks' abstinence) was achieved by 15% of participants at Week 12 and 31% at Week 24. Most adverse events were mild. NVPs may represent a feasible and potentially effective short-to-medium term tobacco smoking cessation aid and/or harm reduction strategy among PLHIV.
HIV 感染者（PLHIV）中有很高的吸烟率。尼古丁雾化产品（NVPs）可能促进戒烟和/或减少伤害。本研究旨在试验 NVPs 在促进 PLHIV 戒烟方面的可行性。烟草危害降低与雾化尼古丁（THRiVe）研究是一项针对 29 名每日使用烟草的 PLHIV 的混合方法试验。参与者试用了为期 12 周的 NVPs 干预。本研究报告了关于烟草戒断和相关不良事件的定量数据的描述性分析。在第 12 周，35%的参与者实现了短期戒烟（7 天点患病率；即 7 天内不使用烟草），而 31%的参与者在第 24 周报告了短期戒烟。在第 12 周，15%的参与者实现了持续的中期戒烟（8 周戒烟），而 31%的参与者在第 24 周实现了持续的中期戒烟。大多数不良事件是轻微的。NVPs 可能代表一种可行的、潜在有效的短期至中期戒烟辅助手段和/或 PLHIV 减少伤害策略。
